This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 3270 results found since Jan 2013.
Distal Chronic Inflammatory Demyelinating Polyneuropathy Following COVID-19 Vaccination in a Patient with Solitary Plasmacytoma: A Case Report and Literature Review
Intern Med. 2023;62(16):2419-2425. doi: 10.2169/internalmedicine.1365-22. Epub 2023 Aug 15.ABSTRACTWe herein report a rare case of distal chronic inflammatory demyelinating polyneuropathy (CIDP) following coronavirus disease 2019 (COVID-19) vaccination. A 39-year-old woman with a solitary plasmacytoma developed general weakness 7 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, which had progressed for 3 months. A neurological examination revealed limb weakness with areflexia. Serological tests identified the presence of IgG antibodies against anti-GM1 and anti-GM2 gangliosides. Comprehensive e...
Source: Internal Medicine - August 16, 2023 Category: Internal Medicine Authors: Takafumi Kubota Tomomi Shijo Kensho Ikeda Yoshihiko Mitobe Shu Umezawa Tatsuro Misu Takafumi Hasegawa Masashi Aoki Source Type: research
Effectiveness and safety of rituximab in autoimmune nodopathy: a single-center cohort study
AbstractAutoimmune nodopathy is a peripheral neuropathy characterized by acquired motor and sensory deficit with autoantibodies against the node of Ranvier or paranodal region in the peripheral nervous system. The clinical and pathological characteristics of the disease are distinct from that of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and the standard treatment for CIDP is partially effective. Rituximab is a chimeric monoclonal antibody which binds and depletes B cells in peripheral blood. This prospective observational study included 19 patients with autoimmune nodopathy. Participants received in...
Source: Journal of Neurology - August 12, 2023 Category: Neurology Source Type: research
Serum B-cell activating factor is not a potential biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy
B-cell activating factor (BAFF) is a crucial cytokine for differentiation and survival of B-cells and correlates to disease activity in some auto-immune diseases. To evaluate BAFF as a biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy (CIDP), serum BAFF levels were measured at varying disease stages: patients starting treatment, patients starting treatment withdrawal, patients in remission and healthy controls. Serum BAFF levels were elevated in patients compared to healthy controls, but did not differ between patients starting treatment and patients in remission.
Source: Journal of Neuroimmunology - August 3, 2023 Category: Allergy & Immunology Authors: Milou R. Michael, Luuk Wieske, Marleen J. Koel-Simmelink, Ivo N. van Schaik, Charlotte E. Teunissen, Filip Eftimov Tags: Short Communication Source Type: research
Myelin barrier breakdown, mechanical hypersensitivity, and painfulness in polyneuropathy with claudin-12 deficiency
CONCLUSION: These results point to a critical role for claudin-12 in maintaining the myelin barrier presumably via Pmp22 and highlight restoration of the hedgehog pathway as a potential treatment strategy for painful inflammatory neuropathy.PMID:37527762 | DOI:10.1016/j.nbd.2023.106246
Source: Neurobiology of Disease - August 1, 2023 Category: Neurology Authors: Jeremy Tsung-Chieh Chen Xiawei Hu Isabel U C Otto Christina Sch ürger Bruno Rogalla von Bieberstein Kathrin Doppler Susanne M Krug Mohammed K Hankir Rosel Blasig Claudia Sommer Alexander Brack Ingolf E Blasig Heike L Rittner Source Type: research
Case report: MELAS and T3271C mitochondrial mutation in an adult woman
ConclusionsTo our knowledge, it's the first report about MELAS with 3271 mutation that have only shown peripheral nerve motion impairment. Proximal weakness is also common in CIDP. In the context of this patient's experience, mitochondrial genome analysis provides an auxiliary criterion for differential diagnosis between MIDs and CIDP. In the meantime, we discussed the clinical effect of GCs on MIDs.
Source: Frontiers in Neurology - July 27, 2023 Category: Neurology Source Type: research
Epidemiology of Chronic Inflammatory Demyelinating Polyneuropathy in South Korea: A Population-Based Study
CONCLUSIONS: The prevalence and incidence rates of CIDP in South Korea were comparable between this nationwide cohort study and previous studies. Common comorbidities such as CVD and diabetes should be appropriately monitored in patients with CIDP to prevent a poor prognosis and socioeconomic burden.PMID:37488959 | DOI:10.3988/jcn.2023.0007
Source: Journal of Clinical Neurology - July 25, 2023 Category: Neurology Authors: Sohee Jung Gucheol Jung Dayoung Kim Jeeyoung Oh Kyomin Choi Source Type: research
